Insider Buying: Immunome (NASDAQ:IMNM) CEO Purchases 46,511 Shares of Stock

Immunome, Inc. (NASDAQ:IMNM) CEO Clay Siegall acquired 46,511 shares of the business’s stock in a transaction dated Thursday, December 18th. The stock was purchased at an average price of $21.50 per share, for a total transaction of $999,986.50. Following the completion of the acquisition, the chief executive officer owned 853,247 shares in the company, valued at approximately $18,344,810.50. This trade represents a 5.77% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Immunome Trading Up 0.9%

NASDAQ:IMNM traded up $0.17 during mid-day trading on Thursday, hitting $19.95. The company had a trading volume of 3,545,568 shares, compared to its average volume of 1,241,242. The business has a fifty day simple moving average of $17.42 and a 200-day simple moving average of $12.55. Immunome, Inc. has a 1 year low of $5.15 and a 1 year high of $25.30. The firm has a market capitalization of $1.83 billion, a price-to-earnings ratio of -6.76 and a beta of 2.17.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. As a group, research analysts anticipate that Immunome, Inc. will post -2.21 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Leerink Partners set a $40.00 price objective on shares of Immunome in a research report on Monday. Guggenheim lifted their price target on Immunome from $25.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday. Wedbush restated an “outperform” rating and issued a $21.00 target price on shares of Immunome in a research report on Friday, November 7th. Stephens lifted their price objective on shares of Immunome from $25.00 to $33.00 and gave the company an “overweight” rating in a research note on Monday, November 17th. Finally, Lake Street Capital increased their price objective on shares of Immunome from $22.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Immunome presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.09.

Hedge Funds Weigh In On Immunome

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. increased its position in Immunome by 37.4% during the first quarter. T. Rowe Price Investment Management Inc. now owns 7,554,594 shares of the company’s stock worth $50,843,000 after buying an additional 2,054,640 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Immunome by 43.4% in the 1st quarter. Vanguard Group Inc. now owns 4,307,191 shares of the company’s stock valued at $28,987,000 after acquiring an additional 1,303,753 shares in the last quarter. Principal Financial Group Inc. boosted its position in Immunome by 222.3% during the third quarter. Principal Financial Group Inc. now owns 1,104,938 shares of the company’s stock worth $12,939,000 after purchasing an additional 762,147 shares during the period. Woodline Partners LP grew its holdings in Immunome by 69.0% during the first quarter. Woodline Partners LP now owns 1,657,729 shares of the company’s stock valued at $11,157,000 after purchasing an additional 676,804 shares during the last quarter. Finally, Driehaus Capital Management LLC bought a new stake in shares of Immunome during the 1st quarter worth $4,109,000. Institutional investors own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.